Advertisement

Breast Cancer Research and Treatment

, Volume 92, Issue 3, pp 207–215 | Cite as

Osteoprotegerin (OPG) Expression by Breast Cancer Cells in vitro and Breast Tumours in vivo – A Role in Tumour Cell Survival?

  • Ingunn Holen
  • Simon S. Cross
  • Helen L. Neville-Webbe
  • Neil A. Cross
  • Sabapathy P. Balasubramanian
  • Peter I. Croucher
  • C. Alyson Evans
  • Jennifer M. Lippitt
  • Robert E. Coleman
  • Colby L. Eaton
Report

Summary

In addition to its role in bone turnover, osteoprotegerin (OPG) has been reported to bind to and inhibit Tumour necrosis factor-related apoptosis inducing ligand (TRAIL). TRAIL is produced in tumours by invading monocytes, inducing apoptosis in neoplastic cells sensitive to this cytokine. OPG production by tumour cells would therefore be a novel mechanism whereby cancer cells evade host defences and gain a growth advantage. In this study we show that OPG produced by breast cancer cells enhances tumour cell survival by inhibiting TRAIL-induced apoptosis. OPG expression by breast cancer cells (MDA-MB 436/231) grown in vitro was examined using PCR and ELISA, and the sensitivity of these cells to TRAIL was determined. The effects of OPG on TRAIL induced apoptosis was investigated by exposing MDA-MB 436 cells to TRAIL, in the presence or absence of OPG, followed by assessment of nuclear morphology. We found that the levels of OPG produced were sufficient to inhibit TRAIL-induced apoptosis, suggesting that OPG may play a role in tumour cell survival. We also examined the expression pattern of OPG in a selection of breast tumours (n=400) by immunohistochemistry, and related OPG expression to the clinico-pathological data for each tumour. OPG expression was found to be negatively correlated with increasing tumour grade. To our knowledge these results are the first to demonstrate that OPG can act as an endocrine survival factor for breast cancer cells, as well as reporting the expression patterns of OPG in a large cohort of human breast tumours.

Key words

apoptosis breast cancer OPG survival TRAIL 

Abbreviations

EGF

epidermal growth factor

OPG

osteoprotegerin

RANKL

receptor activator of nuclear factor κB ligand

TGF

tumour growth factor

TNF

tumour necrosis factor

TRAIL

tumour necrosis factor related apoptosis inducing ligand

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Locksley, RM, Killeen, N, Lenardo, MJ 2001The TNF and TNF receptor superfamilies: integrating mammalian biologyCell104487501CrossRefPubMedGoogle Scholar
  2. 2.
    Kischkel, FC, Hellbardt, S, Behrmann, I, Germer, M, Pawlita, M, Krammer, PH 1995Cytotoxicity-dependent APO-1 (Fas/CD95)- associated proteins form a death-inducing signaling complex (DISC) with the receptorEMBO J1455795588PubMedGoogle Scholar
  3. 3.
    Igney, FH, Krammer, PH 2002Death and anti-death: tumour resistance to apoptosisNat Rev Cancer2277288CrossRefPubMedGoogle Scholar
  4. 4.
    Mueller, H, Flury, N, Liu, R, Scheidegger, S, Eppenberger, U 1996Tumor necrosis factor and interferon are selectively cytostatic in vitro for hormone-dependent and hormone-independent human breast cancer cellsEur J Cancer32A23122318CrossRefPubMedGoogle Scholar
  5. 5.
    Burow, ME, Weldon, CB, Tang, Y, Navar, GL, Krajewski, S, Reed, JC, Hammond, TG, Clejan, S, Beckman, BS 1998Differences in susceptability to tumor necrosis factor alpha-induced apoptosis among MCF-7 cancer cell variantsCancer Res5849404946PubMedGoogle Scholar
  6. 6.
    Ruiz-Ruiz, C, Munoz-Pinedo, C, Lopez-Rivas, A 2000Interferon- gamma treatment elevates caspase-8 expression and sensitises human breast cancer cells to a death receptor-induced mitochondria-operated apoptotic programCancer Res6056735680Google Scholar
  7. 7.
    Burow, ME, Weldon, CB, Tang, Y, McLachlan, JA, Beckman, BS 2001Estrogen-mediated suppression of tumour necrosis factorα-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by antiestrogensJ Steroid Biochem Mol Biol78409418CrossRefPubMedGoogle Scholar
  8. 8.
    Gibson, EM, Henson, ES, Haney, N, Villanueva, J, Gibson, SB 2002Epidermal growth factor protects epithelial-derived cells from tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by inhibiting cytochrome c releaseCancer Res62488496PubMedGoogle Scholar
  9. 9.
    Tobin, SW, Brown, MK, Douville, K, Payne, DC, Eastman, A, Arrick, BA 2001Inhibition of transforming growth factor beta signalling in MCF-7 cells results in resistance to tumor necrosis factor alpha: a role for Bcl-2Cell Growth Differ12109117PubMedGoogle Scholar
  10. 10.
    Almasan, A, Ashkenazi, A 2003Apo2L/TRAIL: apoptosis signalling, biology and potential for cancer therapyCytokine Growth Factor Rev14337348CrossRefPubMedGoogle Scholar
  11. 11.
    Zhang, XD, Nguyen, T, Thomas, WD, Sanders, JE, Hersey, P 2000Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell typesFEBS Lett482193199CrossRefPubMedGoogle Scholar
  12. 12.
    Pan, G, O’Rourke, K, Chinnaiyan, AM, Gentz, R, Ebner, R, Ni, J, Dixit, VM 1997The receptor for the cytotoxic ligand TRAILScience276111113CrossRefPubMedGoogle Scholar
  13. 13.
    Walczak, H, Degli-Esposti, MA, Johnson, RS, Smolak, PM, Waugh, JY, Boiani, N 1997TRAIL-R2: a novel apoptosis-mediating receptor for TRAILEMBO J1653865397CrossRefPubMedGoogle Scholar
  14. 14.
    Noesel, MM, Bezouw, S, Salomons, GS, Voute, PA, Pieters, R, Baylin, SB 2002Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylationCancer Res6221572161PubMedGoogle Scholar
  15. 15.
    Emery, JG, McDonnell, P, Burke, MB, Deen, KC, Lyn, S, Silverman, C 1998Osteoprotegerin is a receptor for the cytotoxic ligand TRAILJ Biol Chem2731436314367CrossRefPubMedGoogle Scholar
  16. 16.
    Spalding, AC, Jotte, RM, Scheinman, RI, Geraci, MW, Clarke, P, Tyler, KL, Johnson, GL 2002TRAIL and inhibitors of apoptosis are opposing determinants for NF-kappaB-dependent, genotoxin-induced apoptosis of cancer cellsOncogene21260271CrossRefPubMedGoogle Scholar
  17. 17.
    Thomas, RJ, Guise, TA, Yin, JJ, Elliott, J, Horwood, NJ, Martin, TJ, Gillespie, MT 1999Breast cancer cells interact with osteoblasts to support osteoclast formationEndocrinology14044514458CrossRefPubMedGoogle Scholar
  18. 18.
    Holen, I, Croucher, PI, Hamdy, FC, Eaton, CL 2002Osteoprotegerin (OPG) is a survival factor for human prostate cancer cellsCancer Res6216191623PubMedGoogle Scholar
  19. 19.
    Shipman, CM, Croucher, PI 2003Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cellsCancer Res63912916PubMedGoogle Scholar
  20. 20.
    Nyambo, R, Cross, N, Lippitt, J, Holen, I, Bryden, G, Hamdy, FC, Eaton, CL 2004Human bone marrow stromal cells protect prostate cancer cells from TRAIL-induced apoptosisJ Bone Miner Res1017121721Google Scholar
  21. 21.
    Neville-Webbe, HL, Cross, NA, Eaton, CL, Nyambo, R, Evans, CA, Coleman, RE, Holen, I 2004Osteoprotegerin (OPG) produced by bone␣marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosisBreast Cancer Res Treat86269279CrossRefPubMedGoogle Scholar
  22. 22.
    Simonet, WS, Lacey, DL, Dunstan, C, Kelley, M, Chang, M-S, Luthy, R 1997Osteoprotegerin: a novel secreted protein involved in the regulation of bone densityCell89309319CrossRefPubMedGoogle Scholar
  23. 23.
    Tsuda, E, Goto, M, Mochizuki, S, Yano, K, Kobayashi, F, Morinaga, T 1997Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesisBiochem Biophys Res Comm234137142CrossRefPubMedGoogle Scholar
  24. 24.
    Ito, R, Nakayama, H, Yoshida, K 2003Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinomaVirchows Arch443146151CrossRefPubMedGoogle Scholar
  25. 25.
    Reinholz, MM, Iturria, SJ, Roche, PC 2002Differential gene expression of TGF-beta family members and osteopontin in breast tumour tissue: analysis by real-time quantitative PCRBreast Cancer Res Treat74255269CrossRefPubMedGoogle Scholar
  26. 26.
    Hofbauer, LC, Heufelder, AE 2000The role of receptor activator of nuclear factor κB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseaseJ Clin Endocrinol Metab8523552363CrossRefPubMedGoogle Scholar
  27. 27.
    MacFarlane, M, Merrison, W, Dinsdale, D, Cohen, GM 2000Active caspases and cleaved cytokeratins are sequestered into cytoplasmic inclusions in TRAIL-induced apoptosisJ Cell Biol14812391254CrossRefPubMedGoogle Scholar
  28. 28.
    Lee, YJ, Froelich, CJ, Fujita, N, Tsuruo, T, Kim, JH 2004Reconstitution of caspase-3 confers low glucose-enhanced tumor necrosis factor-related apoptosis-inducing ligand cytotoxicity and Akt cleavageClin Cancer Res1018941900PubMedGoogle Scholar
  29. 29.
    Oba T, Sun X, Grubbs B, Cui Y, Kakonen, Guise TA, Chirgwin JM: Effects of tumor secretion on recombinant osteoprotegerin (OPG) on osteolytic metastases. ASBMR 23rd annual meeting, Abstract F066, 2001.Google Scholar
  30. 30.
    Fischer JL, Thomas RJ, Elloitt J, Dunstan CR, Choong PFM, Martin TJ, Gillespie MT: Over-expression of native OPG by breast cancer cells enhances tumour growth in bone. ASBMR 24th annual meeting, Abstract SA081, 2002.Google Scholar
  31. 31.
    Truneh, A, Sharma, S, Silverman, C, Khandekar, S, Reddy, MP, Deen, KC, McLaughlin, MM, Srinivasula, SM, Livi, GP, Marshall, LA, Alnemri, ES, Williams, WV, Doyle, ML 2000Temperature-sensitive differential affinity of TRAIL for its receptors DR5 is the highest affinity receptorJ Biol Chem2752331923325CrossRefPubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Ingunn Holen
    • 1
    • 3
  • Simon S. Cross
    • 1
  • Helen L. Neville-Webbe
    • 1
  • Neil A. Cross
    • 1
    • 2
  • Sabapathy P. Balasubramanian
    • 2
  • Peter I. Croucher
    • 1
    • 2
  • C. Alyson Evans
    • 1
  • Jennifer M. Lippitt
    • 1
    • 2
  • Robert E. Coleman
    • 1
  • Colby L. Eaton
    • 1
    • 2
  1. 1.Bone Oncology Group, Division of Genomic MedicineUniversity of SheffieldUK
  2. 2.Division of Clinical Sciences South, School of Medicine and Biomedical SciencesUniversity of SheffieldUK
  3. 3.Clinical Oncology, Genomic Medicine, School of Medicine and Biomedical SciencesUniversity of SheffieldSheffieldUK

Personalised recommendations